Josiah Zayner in his home lab.
[Editor's Note: This op/ed appears in response to January's Big Moral Question: "Where should we draw a line, if any, between the use of gene editing for the prevention and treatment of disease, and for cosmetic enhancement?" Currently, it is illegal to develop human trials for the latter in the U.S.]
Homo sapien: a bipedal primate that is thought to be the only animal to construct a moral code. Despite the genetic differences between members of our species being less than 1 percent, we come in all shapes, sizes and colors. There is no normal for human genetics.
I believe genetic freedom is the most basic human right we all should have.
One DNA base change here, another there brings us humans with light skin, red hair and big muscles. Want to be an NBA All-Star? Your genes are by far the largest determinant of your height and well, there has never been an All-Star under 5'9". Sexual reproduction makes it so that our physical traits seem more a pinch of this and a dash of that than some precise architectural masterpiece. For the most part we have no control over whether we or our children will be the next Cristiano Ronaldo or are born with a debilitating disease--unless we use genetic engineering.
Anywhere from 64% in the US to over 82% of people in China support genetic modification of individuals to help treat diseases. I imagine that number will only increase as people become more familiar with the technology and I don't think most people need convincing that genetic modification for medical treatment is a good thing. In fact, most modern drugs are genetic regulation on a fundamental level. But cosmetic genetic modification is far more controversial with only 39% of people in the US finding it agreeable. Far fewer people support modifying the genes of babies before they are born. My question is: Where does one draw a line between cosmetic and medical genetic changes?
Modifying the genetics of individuals for medical reasons started in the late 1980s and early 1990s when scientists reprogrammed viruses so that instead of causing harm when they infected people, they changed the genetics of their cells. Much has changed and and despite the success of many gene therapy trials, people are still afraid. Perhaps because of concerns over safety, but gene therapies have been tested in over 2000 clinical trials in hundreds of thousands of people. So what are we so afraid of? I asked myself that same question in 2016 and could not find a basis for the fear and so performed the first successfully cosmetic human genetic modification by putting a jellyfish gene in my skin. The experiment was simple, the monetary cost minimal, and though my skin didn't fluoresce like a jellyfish, DNA testing showed it worked and the experiment showed me what was possible.
People are afraid because we are on the cusp of the human race changing as we know it. But isn't that change all we have been striving for?
In late 2017, I wanted to explore bigger cosmetic changes, so I did another genetic experiment on myself; I injected myself with a CRISPR/Cas9 system meant to modify myostatin, a gene responsible for muscle growth and fat loss. I didn't do it because I wanted bigger muscles but because the myostatin gene is a well-studied target that has been modified in many mammals using CRISPR. I feel a responsibility to try and push boundaries that scientists in universities and large corporations can't because of committees, regulations and social acceptability. When this cutting-edge technique was tried for the first time, it wasn't in an expensive lab and it didn't cost millions of dollars. It was done by me, prepared in my home lab, and the cost of this cosmetic treatment was under $500.
Home genetic engineering lab kits like this are sold by Zayner's company for less than $2000.
I have had many people call me crazy and worse, but they don't understand that I've undertaken these experiments with much thought and hesitation. Experimenting on oneself isn't fun; it is an unfortunate situation to be in as a Ph.D. scientist who less than two years ago was fulfilling a prestigious synthetic biology fellowship at NASA. The data points to the experiment being relatively safe, and similar experimental protocols have had success, so why wait? When so much is at stake, we need to show people what is possible so that one day we all can have genetic freedom.
Zayner's arm after attempting the first CRISPR injection showed little immune response; a small red dot in the upper left forearm can be seen at the injection site.
People are afraid because we are on the cusp of the human race changing as we know it. But isn't that change all we have been striving for yet unable to obtain? Have too much or too little hair? There is a non-gene therapy treatment for that. Want to change your appearance? The global cosmetic surgery market is over $15 billion. Tattoos, dyed hair and piercings abound. We sculpt our appearance by exercise, make-up, drugs, chemicals and invasive surgeries. We try so hard to fight against our genetics in every way except genetic modification.
Being human means freedom to be who we want to be. And at the moment, no one gets to choose their genetics. Instead, nature plays a probabilistic role in the most primitive genetic engineering experiment of sexual reproduction. This dice roll can sometimes end in tragedy. Fortunately, in my case I was born with the genetics of a healthy individual. Still, I push for everyone and though my newest genetic modification experiment is ongoing, even if it doesn't work, it is only a matter of time until it does in someone.
If you prevent someone like me from changing my genetics, where do you draw the line? Only people who can't walk can get genetic modification? Only people who can't run? Only people who are predisposed to skin cancer? Don't we all deserve a choice or to give parents better ones? I believe genetic freedom is the most basic human right we all should have. We no longer need to be slaves to genetics so let's break those bonds and embrace the change brought about by allowing human genetic engineering for all no matter the reason.
[Ed. Note: Check out the opposite perspective: "Hacking Your Own Genes: A Recipe for Disaster." Then follow LeapsMag on social media to share your opinion.]
Today's podcast episode features Doug Drysdale, CEO of Cybin, a company that is leading innovations in psilocybin, mushrooms that may help people with anxiety and depression.
Listen on Apple | Listen on Spotify | Listen on Stitcher | Listen on Amazon | Listen on Google
These mushrooms have been used for religious, spiritual and medicinal purposes for thousands of years, but only in the past several decades have scientists brought psychedelics into the lab to enhance them and maximize their therapeutic value.
Today’s podcast guest, Doug Drysdale, is doing important work to lead this effort. Drysdale is the CEO of a company called Cybin that has figured out how to make psilocybin more potent, so it can be administered in smaller doses without side effects.
The natural form of psilocybin has been studied increasingly in the realm of mental health. Taking doses of these mushrooms appears to help people with anxiety and depression by spurring the development of connections in the brain, an example of neuroplasticity. The process basically shifts the adult brain from being fairly rigid like dried clay into a malleable substance like warm wax - the state of change that's constantly underway in the developing brains of children.
Neuroplasticity in adults seems to unlock some of our default ways of of thinking, the habitual thought patterns that’ve been associated with various mental health problems. Some promising research suggests that psilocybin causes a reset of sorts. It makes way for new, healthier thought patterns.
So what is Drysdale’s secret weapon to bring even more therapeutic value to psilocybin? It’s a process called deuteration. It focuses on the hydrogen atoms in psilocybin. These atoms are very light and don’t stick very well to carbon, which is another atom in psilocybin. As a result, our bodies can easily breaks down the bonds between the hydrogen and carbon atoms. For many people, that means psilocybin gets cleared from the body too quickly, before it can have a therapeutic benefit.
In deuteration, scientists do something simple but ingenious: they replace the hydrogen atoms with a molecule called deuterium. It’s twice as heavy as hydrogen and forms tighter bonds with the carbon. Because these pairs are so rock-steady, they slow down the rate at which psilocybin is metabolized, so it has more sustained effects on our brains.
Cybin isn’t Drysdale’s first go around at this - far from it. He has over 30 years of experience in the healthcare sector. During this time he’s raised around $4 billion of both public and private capital, and has been named Ernst and Young Entrepreneur of the Year. Before Cybin, he was the founding CEO of a pharmaceutical company called Alvogen, leading it from inception to around $500 million in revenues, across 35 countries. Drysdale has also been the head of mergers and acquisitions at Actavis Group, leading 15 corporate acquisitions across three continents.
In this episode, Drysdale walks us through the promising research of his current company, Cybin, and the different therapies he’s developing for anxiety and depression based not just on psilocybin but another psychedelic compound found in plants called DMT. He explains how they seem to have such powerful effects on the brain, as well as the potential for psychedelics to eventually support other use cases, including helping us strive toward higher levels of well-being. He goes on to discuss his views on mindfulness and lifestyle factors - such as optimal nutrition - that could help bring out hte best in psychedelics.
Show links:
Doug Drysdale full bio
Doug Drysdale twitter
Cybin website
Cybin development pipeline
Cybin's promising phase 2 research on depression
Johns Hopkins psychedelics research and psilocybin research
Mets owner Steve Cohen invests in psychedelic therapies
Doug Drysdale, CEO of Cybin
Immune cells battle an infection.
Measuring immune resilience
The researchers measured immune resilience in two ways. The first is based on the relative quantities of two types of immune cells, CD4+ T cells and CD8+ T cells. CD4+ T cells coordinate the immune system’s response to pathogens and are often used to measure immune health (with higher levels typically suggesting a stronger immune system). However, in 2021, the researchers found that a low level of CD8+ T cells (which are responsible for killing damaged or infected cells) is also an important indicator of immune health. In fact, patients with high levels of CD4+ T cells and low levels of CD8+ T cells during SARS-CoV-2 and HIV infection were the least likely to develop severe COVID and AIDS.
Individuals with optimal levels of immune resilience were more likely to live longer.
In the same 2021 study, the researchers identified a second measure of immune resilience that involves two gene expression signatures correlated with an infected person’s risk of death. One of the signatures was linked to a higher risk of death; it includes genes related to inflammation — an essential process for jumpstarting the immune system but one that can cause considerable damage if left unbridled. The other signature was linked to a greater chance of survival; it includes genes related to keeping inflammation in check. These genes help the immune system mount a balanced immune response during infection and taper down the response after the threat is gone. The researchers found that participants who expressed the optimal combination of genes lived longer.
Immune resilience and longevity
The researchers assessed levels of immune resilience in nearly 50,000 participants of different ages and with various types of challenges to their immune systems, including acute infections, chronic diseases, and cancers. Their evaluation demonstrated that individuals with optimal levels of immune resilience were more likely to live longer, resist HIV and influenza infections, resist recurrence of skin cancer after kidney transplant, survive COVID infection, and survive sepsis.
However, a person’s immune resilience fluctuates all the time. Study participants who had optimal immune resilience before common symptomatic viral infections like a cold or the flu experienced a shift in their gene expression to poor immune resilience within 48 hours of symptom onset. As these people recovered from their infection, many gradually returned to the more favorable gene expression levels they had before. However, nearly 30% who once had optimal immune resilience did not fully regain that survival-associated profile by the end of the cold and flu season, even though they had recovered from their illness.
Intriguingly, some people who are 90+ years old still have optimal immune resilience, suggesting that these individuals’ immune systems have an exceptional capacity to control inflammation and rapidly restore proper immune balance.
This could suggest that the recovery phase varies among people and diseases. For example, young female sex workers who had many clients and did not use condoms — and thus were repeatedly exposed to sexually transmitted pathogens — had very low immune resilience. However, most of the sex workers who began reducing their exposure to sexually transmitted pathogens by using condoms and decreasing their number of sex partners experienced an improvement in immune resilience over the next 10 years.
Immune resilience and aging
The researchers found that the proportion of people with optimal immune resilience tended to be highest among the young and lowest among the elderly. The researchers suggest that, as people age, they are exposed to increasingly more health conditions (acute infections, chronic diseases, cancers, etc.) which challenge their immune systems to undergo a “respond-and-recover” cycle. During the response phase, CD8+ T cells and inflammatory gene expression increase, and during the recovery phase, they go back down.
However, over a lifetime of repeated challenges, the immune system is slower to recover, altering a person’s immune resilience. Intriguingly, some people who are 90+ years old still have optimal immune resilience, suggesting that these individuals’ immune systems have an exceptional capacity to control inflammation and rapidly restore proper immune balance despite the many respond-and-recover cycles that their immune systems have faced.
Public health ramifications could be significant. Immune cell and gene expression profile assessments are relatively simple to conduct, and being able to determine a person’s immune resilience can help identify whether someone is at greater risk for developing diseases, how they will respond to treatment, and whether, as well as to what extent, they will recover.
